MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value

Table 1 Patient characteristics of long-term and short-term survivors

		Long-term survivor	Short-term survivor
Sex	Male	18 (67%)	12 (50%)
Sex	Female	9 (33%)	12 (50%)
Median age at diagnosis in years (range)		50.5 (34.0–68.1)	70.0 (35.7–83.9)
Median follow-up time in years (range)		4.8 (3.1–8.6)	0.4 (0.0–0.9)
Vital status at end of individual follow-up	Alive	10 (37%)	0 (0%)
Vital status at end of individual follow-up	Dead	17 (63%)	24 (100%)
Subentity	Glioblastoma	22 (81%)	24 (100%)
	Giant cell glioblastoma	1 (4%)	0
	Gliosarcoma	3 (11%)	0
	Epithelioid glioblastoma	1 (4%)	0
Tumor location	Frontal	12 (44%)	2 (8%)
	Temporal	7 (26%)	9 (38%)
	Parietal	5 (19%)	11 (46%)
	Occipital	3 (11%)	2 (8%)
Laterality	Left	14 (52%)	12 (50%)
Laterality	Right	13 (48%)	12 50%)
Temozolomide administration		27 (100%)	11 (46%)

Comparison of features from long-term (more than 3 years overall survival) and short-term survivors (less than 1 year overall survival) are depicted based on sex, median age at initial diagnosis and median follow-up time in years, individual vital status at the end of the follow-up (May 2016), tumor location, subentity and temozolomide administration

ISSN: 2051-5960